BACKGROUND: The incidence of primary hepatic malignancies including Hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) is on the rise. (i) Surgery remains the mainstay of potential curative treatment, however the vast majority of patients will recur and not be amenable to curative therapy. (ii) Inflammation has been associated with poor prognosis, however there is no preoperative marker that can predict recurrence-free- or overall survival. Our aim is to correlate inflammation measured as neutrophil extracellular traps (NETs) with survival. METHODS: A retrospective analysis was performed using sera/tissue from patients with hepatic malignancies. NET levels were measured in the serum (MPO-DNA) or tumor (Cit-H3). Log rank analysis for RFS/OS was performed. RESULTS: Cancer patients had higher pre-surgery MPO-DNA levels compared to healthy individuals (healthy vs cancer: 2.6 ± 1.0 ng/ml vs 34.7 ± 2.13 ng/ml; p < 0.0001). High pre-surgery serum NET levels were associated with shorter RFS/OS compared to those with low levels (RFS-HCC: HR: 2.91, 95% CI: 1.61-5.26, p < 0.0001, RFS-CC: HR: 3.22, 95% CI: 1.33-7.77 p < 0.0093). High Cit-H3 tumor levels similarly predicted shorter RFS/OS. CONCLUSION: The current study shows a correlation between pre-operative NET levels and survival. Studying NET formation as a biomarker pre-surgery can help identify patients that could benefit from closer follow-up due to higher risk for recurrence.
BACKGROUND: The incidence of primary hepatic malignancies including Hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) is on the rise. (i) Surgery remains the mainstay of potential curative treatment, however the vast majority of patients will recur and not be amenable to curative therapy. (ii) Inflammation has been associated with poor prognosis, however there is no preoperative marker that can predict recurrence-free- or overall survival. Our aim is to correlate inflammation measured as neutrophil extracellular traps (NETs) with survival. METHODS: A retrospective analysis was performed using sera/tissue from patients with hepatic malignancies. NET levels were measured in the serum (MPO-DNA) or tumor (Cit-H3). Log rank analysis for RFS/OS was performed. RESULTS: Cancer patients had higher pre-surgery MPO-DNA levels compared to healthy individuals (healthy vs cancer: 2.6 ± 1.0 ng/ml vs 34.7 ± 2.13 ng/ml; p < 0.0001). High pre-surgery serum NET levels were associated with shorter RFS/OS compared to those with low levels (RFS-HCC: HR: 2.91, 95% CI: 1.61-5.26, p < 0.0001, RFS-CC: HR: 3.22, 95% CI: 1.33-7.77 p < 0.0093). High Cit-H3 tumor levels similarly predicted shorter RFS/OS. CONCLUSION: The current study shows a correlation between pre-operative NET levels and survival. Studying NET formation as a biomarker pre-surgery can help identify patients that could benefit from closer follow-up due to higher risk for recurrence.
Authors: Dean J Arnaoutakis; Michael N Mavros; Feng Shen; Sorin Alexandrescu; Amin Firoozmand; Irinel Popescu; Matthew Weiss; Christopher L Wolfgang; Michael A Choti; Timothy M Pawlik Journal: Ann Surg Oncol Date: 2014-01 Impact factor: 5.344
Authors: David F Colón; Carlos W Wanderley; Marcelo Franchin; Camila M Silva; Carlos H Hiroki; Fernanda V S Castanheira; Paula B Donate; Alexandre H Lopes; Leila C Volpon; Silvia K Kavaguti; Vanessa F Borges; Cesar A Speck-Hernandez; Fernando Ramalho; Ana P Carlotti; Fabio Carmona; Jose C Alves-Filho; Foo Y Liew; Fernando Q Cunha Journal: Crit Care Date: 2019-04-08 Impact factor: 9.097
Authors: Sivan Berger-Achituv; Volker Brinkmann; Ulrike Abu Abed; Lars I Kühn; Jonathan Ben-Ezra; Ronit Elhasid; Arturo Zychlinsky Journal: Front Immunol Date: 2013-03-06 Impact factor: 7.561
Authors: Richard E Kast; Alex Alfieri; Hazem I Assi; Terry C Burns; Ashraf M Elyamany; Maria Gonzalez-Cao; Georg Karpel-Massler; Christine Marosi; Michael E Salacz; Iacopo Sardi; Pieter Van Vlierberghe; Mohamed S Zaghloul; Marc-Eric Halatsch Journal: Cancers (Basel) Date: 2022-05-23 Impact factor: 6.575
Authors: Samer Tohme; Hamza O Yazdani; Amaan Rahman; Sanah Handu; Sidrah Khan; Tanner Wilson; David A Geller; Richard L Simmons; Michele Molinari; Christof Kaltenmeier Journal: Can J Gastroenterol Hepatol Date: 2021-11-30
Authors: J Cedervall; M Herre; A Dragomir; F Rabelo-Melo; A Svensson; C Thålin; A Rosell; V Hjalmar; H Wallén; H Lindman; G Pejler; E Hagström; M Hultström; A Larsson; A K Olsson Journal: Oncoimmunology Date: 2022-03-14 Impact factor: 8.110
Authors: Robin Zenlander; Sebastian Havervall; Maria Magnusson; Jennie Engstrand; Anna Ågren; Charlotte Thålin; Per Stål Journal: Sci Rep Date: 2021-09-09 Impact factor: 4.379